Thirty years have witnessed dramatic changes in the manner in which we diagnose and manage prostate cancer.
With prostate-specific antigen screening, there was a shift towards smaller, clinically localized tumors. Tumors are often multifocal and display phenotypic and molecular heterogeneity. Pathologic evaluation of tissue obtained by needle biopsy remains the gold standard for the diagnosis and risk assessment of prostate cancer. Years of experience with grading, along with changes in the amount of biopsy tissue obtained and diagnostic tools available, have produced shifts in grading practices among genitourinary pathologists. Trends in Gleason grading and advances in pathological risk assessment are reviewed with particular emphasis on recent Gleason grading modifications of the International Society of Urologic Pathology. Efforts to maximize the amount of information from pathological specimens, whether it be morphometric, histochemical, or molecular, may improve predictive accuracy of prostate biopsies. New diagnostic techniques are needed to optimize management decisions.
Written by:
Lucia MS, Bokhoven Av. Are you the author?
Department of Pathology, University of Colorado Denver, 12801 E, 17th Ave, Mail Stop 8104, Aurora, CO 80045.
Reference: J Natl Cancer Inst Monogr. 2012;2012(45):157-61.
doi: 10.1093/jncimonographs/lgs029
PubMed Abstract
PMID: 23271767
UroToday.com Prostate Cancer Section
